Global Research Company Announces Worldwide Option & License Agreement For Alzheimer's Treatment
ACI-24.060 represents a cutting-edge approach in the battle against Alzheimer's disease.
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising candidate ACI-24.060, for the treatment of Alzheimer's disease. This collaboration marks a significant step forward in the pursuit of innovative treatments for Alzheimer's, a condition that affects millions of individuals worldwide and poses profound challenges to healthcare systems globally. $AC Immune(ACIU.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
